Clinical Trial: Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07824973) titled 'Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing' on Sept. 11.

Brief Summary: Ketamine is a medicine used in psychiatry for treatment-resistant depression. This study compares two ways of framing ketamine treatment: a psychedelic framing and a biomedical framing. The study will examine whether the framing affects depressive symptoms, treatment experience, tolerability, and longer-term outcomes.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Treatment Resistant Depression (TRD)

Intervention: BEHAVIORAL: Psychedelic framing

The intervention includes:

* Psychedelic framed patient...